PI

Zhibin Li

PI researcher, master's advisor, and postdoctoral co-supervisor.

Email：lzbszu@163.com

PI介绍

Researcher at Shenzhen Institute of Translational Medicine, Shenzhen Second People's Hospital, and Biomedical Research Center of Shenzhen University First Affiliated Hospital. Holds a PhD in Cell Biology, serving as a dedicated Principal Investigator (PI), recipient of the "Hong Kong Scholars" Postdoctoral Fellowship and classified as a high-level talent (Class C) in Shenzhen. Currently serves as a member of the Nano Branch of the Guangdong Society of Precision Medicine Applications and the Burn Surgery Branch of the Chinese Medical Association. Research focuses on nanomedicine delivery and biocompatible materials for wound repair. Principal Investigator of 2 National Natural Science Foundation projects, 5 provincial and ministerial-level projects, and 2 projects in Shenzhen. As first or corresponding author, has published 15 SCI research papers in journals such as Angew. Chem. Int. Ed., Biomaterials, Adv. Sci., and Adv. Healthcare Mater., and holds 10 granted national invention patents.

教育背景

From November 2016 to November 2018, funded by the "Hong Kong Scholars Program," visited and exchanged at the Plasma Laboratory of City University of Hong Kong.

From September 2008 to June 2014, obtained a Ph.D. in Cell Biology from South China Normal University (combined Master's and Ph.D. program).

工作经历

From July 2023 to present, Researcher at Biomedical Research Center, Shenzhen Institute of Translational Medicine.

From March 2021 to June 2023, Researcher at Burns and Plastic Surgery Research Center, Shenzhen Institute of Translational Medicine.

From January 2019 to February 2021, Associate Researcher at Materials Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences.

From November 2018 to December 2018, Associate Researcher at Pharmaceutical Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences.

From June 2014 to October 2018, Postdoctoral Researcher at Pharmaceutical Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences.

研究方向和兴趣

Nanoparticle Drug Delivery and Disease Treatment

Wound Healing Biomaterials

科研项目

National Natural Science Foundation of China (NSFC) General Program, 82272299, Construction and Delivery Mechanism Study of Inhalable Injury Airway Targeted Magnetic Nanoparticle Mucus Penetration System, 2023-01 to 2026-12, 520,000 RMB, ongoing, Principal Investigator.

NSFC Youth Fund Project, 81501592, Study on Activated Macrophage-mediated Targeted Permeation Breast Tumor Photothermal Therapy Using Gold Nanorods, 2016-01 to 2018-12, 216,000 RMB, completed, Principal Investigator.

Guangdong Natural Science Foundation General Program, 2020A1515010613, Drug Efficacy Improvement and Delivery Study of Chronic Obstructive Pulmonary Disease Treatment Based on Two-Dimensional Nanomaterials, 2019-10 to 2022-09, 100,000 RMB, completed, Principal Investigator.

Guangdong Provincial Natural Science Foundation-Provincial Enterprise Joint Fund-General Program, Study on Precise Targeting of Macrophage Trojan Horse Strategy for Breast Cancer Metastasis Treatment, 2021-11 to 2024-10, 100,000 RMB, ongoing, Principal Investigator.

Guangdong Provincial Natural Science Foundation Doctoral Startup Fund, 2015A030310210, Study on Tumor Necrosis Factor and Interferon Modified Biomaterials Enhancing Antitumor Immune Response, 2015-08 to 2018-08, 100,000 RMB, completed, Principal Investigator.

Shenzhen Basic Research Key Project, JCYJ20200109115635440, Study on Nanozyme Enhanced CRISPR Effect Protein Activity and Its Detection Applications, 2020-11 to 2023-11, 2,000,000 RMB, ongoing, Principal Investigator.

China Postdoctoral Science Foundation Special Funded Project, 2016T090807, Study on Cell-mediated Gold Nanoparticle Targeted Hypoxic Tumor Radiotherapy Sensitization, 2016-01 to 2017-12, 150,000 RMB, completed, Principal Investigator.

China Postdoctoral Science Foundation General Program, 2015M582445, Study on Macrophage-loaded Nanoparticles for Targeted Photothermal Therapy of Tumors, 2015-09 to 2016-08, 50,000 RMB, completed, Principal Investigator.

Shenzhen-Hong Kong-Macao Science and Technology Cooperation Program (C-Class), SGDX2020110309300301, Development of High-performance Artificial Seed Crystals for High-throughput Protein Crystallization Screening, 2021-07 to 2023-07-31, 1,000,000 RMB, ongoing, Project Leader.

Shenzhen Basic Research Project, JCYJ20150401145529032, Development of New Technology for Immunostimulatory Cell Photothermal Therapy of Breast Cancer, 2015-10 to 2017-10, 100,000 RMB, completed, Principal Investigator.

代表性成果

1. Wang XY^#, Xu KG^#, Mu L, Zhang XQ, Huang GT, Xing MC, Li ZB*, Wu J*. Mussel-derived bioadaptive artifical tendon facilitates the cell proliferation and tenogenesis to promote tendon functional reconstruction. Adv. Healthcare Mater. 2203400 (2023).

2. Xie HH, Geng SY, Shao JD*, Luo GH, Liu Q, Wang JH, Chen Y*, Chu PK, Li ZB*, Yu XF. Niobium diselenide nanosheets: an emerging biodegradable nanoplatform for efficient cancer phototheranostics in the NIR-II window. Adv. Healthcare Mater. 2202126 (2022).

3. Li ZB^#, Luo GH^#, Hu WP^#, Hua JL, Geng SY, Chu PK, Zhang J*, Wang HY*, Yu XF*. Mediated drug release from nano-vehicles by black phosphorus quantum dots for efficient therapy of chronic obstructive pulmonary disease. Angew. Chem. Int. Ed. 59, 20568-20576 (2020).

4. Li ZB, Shao JD, Luo Q, Yu XF*, Xie HH, Fu HD, Tang SY, Wang HY*, Han GL, Chu PK*. Cell-borne 2D nanomaterials for efficient cancer targeting and photothermal therapy. Biomaterials 133, 37-48 (2017).

5. Li ZB, Huang H, Tang SY, Li Y, Yu XF*, Wang HY, Li PH, Sun ZB, Zhang H, Liu CL, Chu PK*. Small gold nanorods laden macrophages for enhanced tumor coverage in photothermal therapy. Biomaterials 74, 144-154 (2016).

6. Qian M^#, Cheng ZQ^#, Luo GH, Galluzzi, M, Shen YH*, Li ZB*, Yang HY*, Yu XF. Molybdenum diphosphide nanorods with laser-potentiated peroxidase catalytic/mild-photothermal therapy of oral cancer. Advanced Science 9, 2101527.

7. Li ZB, Guan YQ*, Liu JM*. The role of STAT-6 as a key transcription regulator in HeLa cell death induced by IFN-γ/TNF-α co-immobilized on nanoparticles. Biomaterials 35, 5016-5027 (2014).

8. Li ZB, Yu XF, Chu PK*. Recent advances in cell-mediated nanomaterial delivery systems for photothermal therapy. J. Mater. Chem. B 6, 1296-1311 (2018).

9. Li ZB^#, Tang SY^#, Wang BK, Li Y, Huang H, Wang HY, Li PH, Li CZ, Chu PK, Yu XF. Metabolizable small gold nanorods: size-dependent cytotoxicity, cell uptake and in vivo biodistribution. ACS Biomater. Sci. Eng. 2, 789-797 (2016).

10. Li ZB^#, Wu L^#, Wang HY*, Zhou WH, Liu HX, Li PH, Chu PK*, Yu XF*. Synergistic antibacterial activity of black phosphorus nanosheets modified with titanium aminobenzenesulfanato complexes. ACS Applied Nanomaterials. 2, 1202-1209 (2019).

代表性发明专利列表：

1.近红外光刺激巨噬细胞分泌外泌体的方法和外泌体；发明人：李志斌、张晓琦；专利号：ZL202310211636.X；授权公告日：2023年6月16日。

2.一种复合聚丙烯酰胺凝胶及其制备方法和应用；发明人：李志斌、吴军、王明慧、木兰；专利号：ZL202110926941.8；授权公告日：2022年11月15日。

3.一种仿过氧化氢酶活性的光催化纳米酶及其制备方法和应用；发明人:李志斌、梅婷婷、喻学锋；专利号：ZL202110244517.5；授权公告日：2022年03月29日。

4.一种载药黑磷壳聚糖复合纳米球的制备方法及应用；发明人：李志斌、喻学锋；专利号：ZL201910482450.1；授权公告日：2022年05月10日。

5.一种抗肿瘤药物、抗肿瘤外敷药及其制备方法；发明人：李志斌、喻学锋；专利号：ZL201810873345.6；授权公告日：2021年09月24日。

6.一种具有快速粘液渗透与药物递送作用的纳米复合微球的制备方法和应用；发明人：李志斌、钱敏、喻学锋；专利号：ZL202010651124.1；授权公告日：2021年06月25日。